Clinical Trial Update: An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

This is a completed Phase 1, open-label pharmacodynamic study evaluating the combination of bevacizumab and pazopanib in renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pazopanib (Pazopanib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Renal Cell | Phase 1 | Status: COMPLETED